The Emergence of Direct-to-Consumer Pharmaceutical Platforms: Strategic Implications for Biopharma

When a growing share of new-to-brand prescriptions in select therapeutic classes originates outside traditional channels, brand strategy itself must evolve. Obesity illustrates this shift. Anti-obesity medicines have demonstrated both the viability of novel commercial channels and the scale of self-directed care: Patients know the therapy they want, actively direct treatment decisions and engage outside traditional pharmaceutical pathways.

This dynamic warrants a reevaluation of pricing, access and channel strategy. In this emerging model, direct-to-consumer (DTC) and cash-pay pathways are not peripheral tactics; they shape affordability anchors and demand generation. Companies that fail to adapt risk ceding influence over both the patient experience and the economic logic of their most important assets.

A changing demand landscape and the rise of DTC and self-pay pathways

The DTC model for prescription pharmaceuticals has moved rapidly from experimentation to mainstream adoption. Digitally enabled, patient-initiated pathways reduce friction, compress time to therapy, and offer flexibility between reimbursement and cash-pay access.

In high-demand categories such as obesity, migraine and metabolic disease, coverage gaps and prior authorization barriers have created meaningful access friction. At the same time, patient comfort with virtual care and consumer-grade digital platforms has raised expectations for speed, transparency and convenience. Together, these forces make DTC a credible channel for conditions characterized by high patient activation and relatively standardized clinical decision-making.

Biopharma leaders are increasingly treating DTC as a durable commercialization component rather than a tactical add-on. Platforms such as LillyDirect, NovoCare and PfizerForAll reflect this shift toward more direct, digitally coordinated engagement (see Figure 1).

Obesity has been the clearest catalyst. Strong demand combined with uneven coverage has produced a sizable self-pay segment, large enough to sustain manufacturer-led pathways outside traditional benefit structures. A growing share of new-to-brand Zepbound prescriptions now originates through LillyDirect, underscoring DTC’s role in therapy initiation. What began as a niche workaround is evolving into a broader model for engaging, initiating and retaining patients in chronic care (see Figure 2).

The evolving DTC value chain: A new commercial architecture

Early DTC efforts were largely promotional or transactional. Today’s models more closely resemble coordinated access architectures that integrate capabilities across the patient experience. Manufacturers increasingly rely on ecosystems of specialized partners spanning telehealth, payments, pharmacy and logistics. No single organization can deliver all capabilities at scale, making thoughtful ecosystem design essential.

Across leading platforms, the DTC journey can be distilled into several core modules:

By bypassing pharmacy benefit managers (PBMs) and wholesalers in self-pay scenarios, these models reduce administrative complexity while enabling multiple engagement pathways. Increasingly, they support both insured and cash-pay patients through a unified experience, expanding choice without adding friction.

Learning from digital health: User experience (UX) lessons from non-biopharma entrants 

Consumer-focused digital health companies such as Hims & Hers, Ro and Noom have set clear expectations for frictionless user experience. Their success reflects a focus on intuitive design, up-front pricing clarity and tightly integrated care models that resonate with patients and increasingly compete with manufacturer-led approaches (see Figure 3).
 

Key non-biopharma UX learnings:

As biopharma scales DTC platforms, matching or exceeding these experience standards will be essential to sustaining patient engagement and trust.

Imperative for biopharma leaders

As DTC and digitally coordinated models mature, the question for commercial executives is no longer whether to participate, but whether they are actively shaping patient engagement for the right assets. These models are not universally applicable. Highly complex, provider-anchored therapies, such as oncology, will remain rooted in traditional care settings. In contrast, medicines characterized by high patient activation, standardized clinical decision-making and meaningful access friction are being increasingly influenced by digital pathways.

For those assets, DTC cannot remain a pilot or side initiative. It requires deliberate executive action across three imperatives:

Competitive advantage will not come from launching a DTC presence alone. It will accrue to organizations that make intentional choices about how they engage patients digitally, where DTC fits within the portfolio and which brands are allowed to meaningfully shape the patient experience.

For more information, please contact us.

L.E.K. Consulting is a registered trademark of L.E.K. Consulting LLC. All other products and brands mentioned in this document are properties of their respective owners. © 2026 L.E.K. Consulting LLC